Main
ASCVD, TG, various dyslipidemias
ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, ASCVD
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality worldwideAngiopoietin-like protein 3 (ANGPTL3), a member of the angiopoietin-like family of proteins, is a hepatokine exclusively secreted by the liver and a key regulator of serum lipid and lipoprotein metabolism. ANGPTL3 inhibits lipoprotein lipase (LPL), thereby regulating the intravascular clearance of TG. It also inhibits endothelial lipase, which is involved in the catabolism of HDL-C and very-low-density lipoprotein cholesterol (VLDL-C)In humans, homozygous loss-of-function mutations in Pharmacological inhibition of ANGPTL3 with evinacumab, a monoclonal antibody, and with vupanorsen, an antisense oligonucleotide (ASO), have been shown to replicate the phenotype of ARO-ANG3 is a subcutaneously administered, synthetic, double-stranded small interfering RNA (siRNA) molecule targeted to hepatocytes (via conjugation to In this phase 1 study (AROANG1001), a basket trial design was adopted to initially evaluate therapeutic proof of concept in HPs and participants with various dyslipidemias (Extended Data Fig. 